Fremanezumab
Sleep Disorder
Beth Israel Deaconess Medical Centermonoclonal_antibodyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Sleep Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trazodone Johns Hopkins University | Phase 4 | BB |
Armodafinil Cephalon | Phase 4 | BB |
Tvp-1012 Technische Universität Dresden | Phase 4 | BB |
MELATONIN Duke University | Phase 3 | BB |
Olanzapine Central Institute of Psychiatry, Ranchi, India | Phase 4 | BB |
View all 36 →
Same molecule, other indications
Fremanezumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →